Sort   by:  
 Page size 
UnknownPrediction of disability-free survival in healthy older people.
Prolonging survival in good health is a fundamental societal goal. However, the leading determinants of disability-free survival in healthy older people have not been well established. Data from ASPREE, a bi-national placebo-controlled trial of aspirin with 4.7 years median follow-up, was analysed. ...
S-EPMC9213595 | biostudies-literature
UnknownEffect of Aspirin on Disability-free Survival in the Healthy Elderly.

Background

Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disability-free life in healthy seniors is unclear.

Methods

From 2010 through 2014, we enrolled community-...
S-EPMC6426126 | biostudies-literature
UnknownEffect of Aspirin on All-Cause Mortality in the Healthy Elderly.

Background

In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerical...
S-EPMC6433466 | biostudies-literature
UnknownEffect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

Background

Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk.

Methods

From 2010 through 2014, we enrolle...
S-EPMC6289056 | biostudies-literature
Sort   by:  
 Page size